MICA and melanoma: Ferrari de Andrade and collaborators developed an antibody that binds to the MIC-A α3 domain, the site of proteolytic shedding, to avoid MIC-A cleavage, and demonstrated this could increase NK cell cytotoxicity toward human melanoma cells (147).